Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash from Financing Activities (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Cash from Financing Activities for 14 consecutive years, with $75536.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities fell 96.13% year-over-year to $75536.0, compared with a TTM value of $6.0 million through Sep 2025, down 17.86%, and an annual FY2024 reading of $9.3 million, up 171.18% over the prior year.
  • Cash from Financing Activities was $75536.0 for Q3 2025 at Sunshine Biopharma, down from $3.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $29.1 million in Q2 2022 and bottomed at -$2.1 million in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $3.3 million, with a median of $826324.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities plummeted 8758.42% in 2022, then soared 12730.71% in 2025.
  • Year by year, Cash from Financing Activities stood at -$23664.0 in 2021, then tumbled by 8758.42% to -$2.1 million in 2022, then skyrocketed by 98.54% to -$30519.0 in 2023, then soared by 6542.34% to $2.0 million in 2024, then plummeted by 96.16% to $75536.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for SBFM at $75536.0 in Q3 2025, $3.6 million in Q2 2025, and $338137.0 in Q1 2025.